What is the Growth Outlook for Non Invasive Prenatal Testing Market?
The major factors driving the growth of Non Invasive Prenatal Testing market include
the growing preference for non-invasive techniques over invasive methods,
rising focus on reimbursement for NIPT, the launch of new and advanced NIPT
products, and increasing maternal age (growth in the risk of chromosomal
abnormalities in babies)
[144 Pages Report] The global non-invasive prenatal testing
(NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9
billion in 2019, at a CAGR of 13.5% during the forecast period.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690
Report Scope and Market Segmentation:
|
Report Metric |
Details |
|
Market Size Available for Years |
2017–2024 |
|
Base Year Considered |
2018 |
|
Forecast Period |
2019–2024 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
Product and Service, Application, and Region |
|
Geographies Covered |
North America (US and Canada), Europe (Germany,
UK, France, and RoE), Asia, and the Rest of the World |
|
Companies Covered |
Illumina, Inc. (US), Thermo Fisher Scientific
Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US),
F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory
Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health
(UK) |
The services segment is expected to grow at the highest
CAGR during the forecast period.
On the basis of product and service, the NIPT market is
segmented into products and services. The services segment is expected to grow
at the highest CAGR during the forecast period. Factors such as the rising
incidence of genetic disorders, increasing focus on prenatal screening, and
government initiatives to provide prenatal testing services are contributing to
the growth of this market.
The trisomy segment accounted for the largest share of
the market
On the basis of application, the NIPT market is segmented
into trisomy, microdeletion syndrome, and other applications. The trisomy
segment accounted for the largest share of the non-invasive prenatal testing
market. This segment is also expected to register the highest CAGR during the
forecast period.
North America dominated the NIPT market
Growth in the North American market is supported by the
presence of a better reimbursement structure and a favorable funding scenario
for research activities, rising awareness about NIPT, and the increasing demand
for the early detection of birth defects in this region.
Illumina, Inc. (US)
Illumina is one of the major players in the non-invasive
prenatal testing market. The company offers a range of highly interconnected
products related to sequencing, genotyping, gene expression, and molecular
diagnostics. It also offers whole-genome sequencing, genotyping, NIPT, and
support services which further strengthen its market position.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
Comments
Post a Comment